The Latest Breaking News from Eli Lilly

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

The healthcare market shows promise due to heightened demand for quality care, technological advancements, preventive measures, and increased public investment, ensuring resilience in any economic condition. Therefore, investors could now consider top healthcare stocks, such as Eli Lilly (LLY), Merck & Co. (MRK), and Abbott Laboratories (ABT). Keep reading.

Nvidia is expected to boost the S&P 500 Q3 earnings growth rate. Meta Platforms and Alphabet may lift Communications Services earnings.

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

S&P 500 earnings season is kicking off. And some companies are expected to put up some huge numbers — even bigger than Nvidia

The Nasdaq led Tuesday's market rebound. Nvidia powered past another buy point, with many other stocks actionable. AI giant Taiwan Semi reported strong sales.